Background Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab.
Introduction
Immune checkpoint blockade has become a standard of care for the treatment of advanced melanoma. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor ipilimumab was the first immune checkpoint inhibitor to show a survival benefit in patients with advanced melanoma. 1, 2 Subsequently, the programmed death 1 (PD-1) inhibitors pembrolizumab [3] [4] [5] [6] [7] and nivolumab [8] [9] [10] [11] have shown efficacy in previously untreated and ipilimumab-treated advanced melanoma. In the phase 3 KEYNOTE-006 trial, 6, 12 pembrolizumab 10 mg/kg given every 2 weeks or every 3 weeks showed significantly better overall survival, progression-free survival, and objective response than did ipilimumab in patients with advanced melanoma, as well as a lower proportion of grade 3-5 treatment-related adverse events despite the longer treatment exposure of pembrolizumab than of ipilimumab.
CTLA-4 and PD-1 are inhibitory receptors that suppress anti-tumour immune activity at different stages: CTLA-4 interferes with T-cell activation at antigen presentation during the priming phase, whereas PD-1 downregulates T-cell activity at the tumour site during the effector phase. 13 These non-redundant, complementary mechanisms of action led to synergistic anti-tumour activity of combined CTLA-4 and PD-1 inhibition in preclinical models. 14, 15 Clinically, combination of PD-1 and CTLA-4 inhibition has shown efficacy in several clinical trials. 8, 16, 17 In the phase 3 CheckMate 067 trial, 8, 18 combination of reduceddose nivolumab with standard-dose ipilimumab for four doses followed by standard-dose nivolumab alone improved overall survival, progression-free survival, and objective response compared with standard-dose ipilimumab. However, the significant improvement in efficacy was accompanied by increased toxicity, including a high proportion of grade 3-4 treatment-related adverse events, with an associated increase in treatment discontinuation. These findings raised the question of whether or not standard-dose anti-PD-1 combined with reduced-dose ipilimumab could show substantial clinical activity while avoiding severe toxicity.
In the KEYNOTE-029 trial, we assessed the safety and anti-tumour activity of standard-dose pembrolizumab given in combination with reduced-dose ipilimumab in patients with advanced melanoma. In an initial safety run-in that enrolled 22 patients with advanced melanoma or renal cell carcinoma, this combination showed an acceptable safety profile and preliminary evidence of anti-tumour activity. 19 In this study, we present results from the KEYNOTE-029 expansion cohort of patients with advanced melanoma receiving standard-dose pembrolizumab plus reduced-dose ipilimumab.
Methods

Study design and participants
In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA into the expansion cohort (appendix p 2). Eligible patients were aged at least 18 years and had histologically confirmed, unresectable stage III or IV melanoma, excluding uveal melanoma; an Eastern Cooperative Oncology Group performance status of 0 or 1; measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; 20 adequate organ function; resolution of toxic effects of the most recent previous chemotherapy to grade 1 or less (except alopecia); no previous therapy with an anti-PD-1, anti-programmed death ligand 1 (PD-L1), anti-programmed death ligand 2, anti-CD137, or anti-CTLA-4 antibody; no active autoimmune disease requiring systemic steroids or immunosuppressive agents; no active non-infectious pneumonitis; and no uncontrolled thyroid dysfunction or diabetes. We excluded patients with active brain or leptomeningeal metastases; patients with previously treated, stable brain metastases were eligible. All patients were required to provide an adequate archival or newly collected melanoma tissue sample for PD-L1
Research in context
Evidence before this study We searched PubMed on March 15, 2017, using the individual search terms "PD-1" OR "programmed death 1", "PD-L1" OR "programmed death ligand 1", "pembrolizumab" OR "MK-3475" OR "lambrolizumab" OR "keytruda", "nivolumab" OR "BMS-936558" OR "opdivo", "ipilimumab" OR "yervoy", "atezolizumab" OR "MPDL3280A", "durvalumab" OR "MEDI4736", and "avelumab" OR "MSB0010718C". We also did the following combination searches: "nivolumab" AND "ipilimumab" AND "combination", "pembrolizumab" AND "ipilimumab" AND "combination", "PD-1" AND "CTLA-4" AND "combination", and "PD-L1" AND "CTLA-4" AND "combination". We combined all searches with "melanoma" and did not limit them by date, but limited them to the English language. We identified three published clinical trials of nivolumab plus ipilimumab for advanced melanoma: a phase 1 dose-finding trial, the randomised controlled phase 2 CheckMate 069 study, and the randomised controlled phase 3 CheckMate 067 study.
Added value of this study
Data from this study show that combination therapy with standard-dose pembrolizumab and reduced-dose ipilimumab is tolerable and has substantial anti-tumour activity in patients with advanced melanoma. These data suggest that treatment with a standard dose of anti-programmed death 1 therapy and a reduced dose of anti-cytotoxic T-lymphocyte-associated protein 4 therapy is feasible and warrants further exploration.
Implications of all the available evidence
In this large phase 1 trial, the toxicity profile and anti-tumour activity of standard-dose pembrolizumab plus reduced-dose ipilimumab compared favourably with those observed in the phase 3 trial of reduced-dose nivolumab plus standard-dose ipilimumab. These data support use of anti-programmed death 1 and anti-cytotoxic T-lymphocyte-associated protein 4 combination therapy in patients with advanced melanoma and suggest that combination of standard-dose pembrolizumab and reduced-dose ipilimumab might be a viable treatment option for these patients.
See Online for appendix immunohistochemistry. Full inclusion and exclusion criteria are listed in the appendix (pp 3-4).
The study protocol and associated amendments were approved by the appropriate institutional review boards and ethics committees at each centre. We did the study in accordance with the protocol and subsequent amendments, Good Clinical Practice Guidelines, and the Declaration of Helsinki. All patients provided written informed consent.
Procedures
Patients received pembrolizumab 2 mg/kg intravenously for 30 min once every 3 weeks followed by ipilimumab 1 mg/kg intravenously for 90 min once every 3 weeks for four doses, followed by pembrolizumab 2 mg/kg intravenously for 30 min every 3 weeks for up to 2 years. We continued treatment until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision. If an investigator considered an adverse event to be caused by ipilimumab, patients could discontinue ipilimumab and continue pembrolizumab on resolution of the event to grade 0 or 1; if pembrolizumab was discontinued, ipilimumab was discontinued as well. Patients with radiological disease progression who were clinically stable could continue treatment until a scan was done a minimum of 4 weeks later. If progression was confirmed but the patient was clinically stable and considered to be deriving clinical benefit, treatment could be continued. Patients who achieved complete response could discontinue pembrolizumab if they received treatment for at least 24 weeks, maintained complete response for at least two scans after complete response was declared, and received at least two pembrolizumab doses after complete response was confirmed. For full criteria for removal of a patient from the study, and for details of permitted treatment reductions and interruptions, see appendix (pp 64-68). Pembrolizumab dose reductions were not permitted. The ipilimumab dose could be reduced to 0·3 mg/kg after the first occurrence of a grade 3-4 haematological toxicity or grade 3 nonhaematological toxicity that resolved within 4 weeks or after the first occurrence of a grade 1-2 non-haematological toxicity that did not resolve within 4 weeks; ipilimumab was to be discontinued on recurrence.
PD-L1 expression in tumour samples was assessed during the screening period at a central laboratory using an immunohistochemistry assay (Agilent Technologies, Carpinteria, CA, USA) and the 22C3 antibody (Merck & Co, Inc, Kenilworth, NJ, USA). We defined positivity as staining on at least 1% of tumour cells or mononuclear inflammatory cells intercalated within or contiguous to tumour nests. We did tumour imaging at baseline and week 12 and then every 6 weeks until week 30 and every 12 weeks thereafter. Response was assessed according to RECIST version 1.1 20 by independent central review for formal assessment of anti-tumour activity and according to modified RECIST by investigator review for informing treatment decisions. We assessed adverse events, laboratory values, and vital signs regularly throughout the study and graded adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
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Outcomes
The primary objective was to assess the safety and tolerability of pembrolizumab plus ipilimumab on the basis of the prevalence of adverse events, including adverse events of special interest based on an immunological mechanism of action (ie, immunemediated). We derived immune-mediated adverse events from a list of terms specified by the funder (appendix p 6) and included them as immune-mediated events regardless of whether they were considered to be immune related or treatment related by the investigator. Secondary endpoints were the proportion of patients with an objective response (defined as complete or partial res ponse according to RECIST version 1. 1 20 ), duration of response (defined as the time from first evidence of response until disease progression or death), overall survival (defined as the time from enrolment to death from any cause), ordinal response score, and relation between PD-L1 expression according to immuno histo chemistry and objective response, progression-free survival, and overall survival. Progression-free survival (defined as the time from enrolment to radiologically confirmed disease progression or death from any cause) was also assessed in the total population, but was not a prespecified outcome.
Statistical analysis
The results reported in this study are based on an analysis done after all patients had at least 12 months of follow-up. Up to 150 patients were to be enrolled, with a goal of approximately 25% of patients with PD-L1-negative tumours being enrolled to assess the proportion of patients with an objective response in this subgroup. With 22 patients with PD-L1-negative tumours enrolled, the study had 80% power to rule out a lower bound of the proportion of these patients with an objective response of 15% if the true proportion was 40%. We assessed safety (primary outcome) in all patients who received at least one dose of combination therapy. We assessed objective response and overall survival (secondary outcomes) in all enrolled patients. We also assessed progression-free survival in all enrolled patients. We assessed the duration of response (secondary outcome) in all patients who had complete or partial response. We provided descriptive statistics for baseline characteristics, patient disposition, and adverse events. We used the Kaplan-Meier method to estimate progression-free survival, overall survival, and duration of response. We calculated the event rate per 100 person-years of exposure for immune-mediated adverse events as (number of events × 100)/person-years of exposure, in which exposure is defined as minimum (last dose date + 30 or data cutoff date) -first dose date + 1. We did statistical analyses using SAS version 9.3. This trial is registered with ClinicalTrials.gov, number NCT02089685. Enrolment into this cohort is closed, but patients are still being monitored for safety and anti-tumour activity. The originally planned phase 2 part of the trial was not pursued in light of the results of the phase 1 pembrolizumab plus pegylated interferon alfa-2b dose-finding cohort.
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Role of the funding source
Representatives of the funder had a role in study design, data collection, data analysis, data interpretation, and writing of the report. The funder maintained the study database. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Between Jan 13, 2015, and Sept 17, 2015, we enrolled 153 patients, all of whom received at least one dose of pembrolizumab plus ipilimumab (appendix p 5) and thus were evaluable for safety and efficacy. Most patients were previously untreated and had PD-L1-positive tumours, normal serum lactate dehydrogenase concentrations, and an Eastern Cooperative Oncology Group performance status of 0 ( 147 (96%) of 153 patients had at least one treatmentrelated adverse event, including 69 (45%) who had at least one adverse event of grade 3-4 severity (table 2) . No treatment-related deaths occurred. Four (3%) patients died because of non-treatment-releated adverse events: three (2%) because of disease progression and one (1%) because of acute coronary syndrome. Treatment-related adverse events led to discontinuation of ipilimumab only in 12 (8%) patients and pembrolizumab only in 14 (9%) patients. An additional 22 (14%) patients discontinued both ipilimumab and pembrolizumab for treatmentrelated adverse events, including 17 (11%) who discontinued both treatments for the same adverse event and five (3%) who discontinued ipilimumab for one event and later discontinued pembrolizumab for another. 13 (27%) of the 48 patients who discontinued treatment because of treatment-related adverse events did so because of laboratory abnormalities. Four (3%) of 153 patients had their ipilimumab dose reduced because of treatmentrelated adverse events: three (2%) because of increased lipase concentration and one (1%) because of autoimmune hepatitis. During pembrolizumab mono therapy, 44 (29%) patients interrupted therapy because of treatment-related adverse events. Data are n (%) and listed in order of descending total prevalence. n=153. Relationship to study treatment was established by the investigator. We included grade 1-2 events if they occurred in at least 10% of patients. All grade 3-4 events are included. Median time to onset of immune-mediated adverse events that occurred in more than one patient ranged from 26 days to 310 days (figure 1). Exposure-adjusted event rates were highest in the first 3 months of treatment for all immune-mediated adverse events except for the low-frequency events (adrenal insufficiency, myositis, and uveitis), for which the event rates were highest from 3 months to 6 months after starting treatment (figure 1). At data cutoff, 88 (56%) of the 158 immune-mediated events had resolved, including 37 (74%) of 50 grade 3-4 events (appendix p 11). Excluding endocrinopathies, 65 (80%) of 81 immune-mediated events of any grade resolved and 33 (83%) of 40 grade 3-4 events resolved. Considering individual events, hypophysitis, adrenal insufficiency, and hypothyroidism were the least frequently resolved, whereas all cases of hepatitis, pancreatitis, and uveitis resolved by data cutoff.
After a median follow-up of 17·0 months, 93 (61% [95% CI 53-69]) of 153 patients had an objective response (table 4) . 114 (82%) of 139 assessable patients had a decrease from baseline in tumour size, and the median change from baseline was -63% (figure 2). The proportion of patients with an objective response was similar in patients with PD-L1-positive and PD-L1-negative tumours (table 4) . The proportion of patients with an objective response was also similar in other subgroups examined, including previous treatment, baseline lactate de hydrogenase concentration, and BRAF mutation, with overlapping 95% CIs (appendix p 12 figure 2 ). Overall survival according to PD-L1 expression is not presented because the number of deaths that have accrued is not sufficient to do a meaningful subgroup analysis. Ordinal response score results are being analysed and might be presented elsewhere on completion. Uveitis (n=4) Pancreatitis (n=5) Pneumonitis (n=16) Hypothyroidism (n=25) Nephritis (n=3) Hepatitis (n=15) Hypophysitis (n=16) Colitis (n=14) Hyperthyroidism (n=17) Thyroiditis ( 
Discussion
In this expansion cohort of a phase 1b trial, we show that combination of standard-dose pembrolizumab with reduced-dose ipilimumab had a manageable toxicity profile and substantial anti-tumour activity.
At the time that this study was done, pembrolizumab 2 mg/kg every 3 weeks was the standard dose of pembrolizumab approved by the US Food and Drug Administration and European Medicines Agency on the basis of the results of pharmacokinetic analyses 23 and randomised dose comparisons showing similar efficacy and safety for both 2 mg/kg and 10 mg/kg every 3 weeks 4, 7 and 10 mg/kg both every 2 weeks and 3 weeks. 6, 7 The combination of standard-dose pembrolizumab with reduced-dose ipilimumab explored in this study was associated with higher toxicity than that reported for pembrolizumab or ipilimumab monotherapy. 1, 4, [6] [7] [8] 17 Hypothyroidism was more frequent with the combination than with pembrolizumab monotherapy (16% vs 5-10%), as were hyperthyroidism (11% vs 2-5%), and pneumonitis (10% vs 1-3%). 4, 6, 7 Toxicities typically associated with ipilimumab were also more frequent with the combination than were those reported for ipilimumab monotherapy, including hepatitis (10% vs 1-4%) and hypophysitis (10% vs 2%). 1, 6, 8, 17 By contrast, the toxicity profile of standard-dose pembrolizumab plus reduced-dose ipilimumab compared favourably with that of reduced-dose nivolumab combined with standard-dose ipilimumab. Some ipilimumabassociated toxicities appear to be more frequent with the nivolumab plus ipilimumab combination (eg, colitis [12%] and diarrhoea [44%]) than with the pembrolizumab plus ipilimumab combination (colitis [9%] and diarrhoea [26%]), whereas some anti-PD-1-associated toxicities seem to be more frequent with the pembrolizumab plus ipililumab combination (eg, pneumonitis [10%]) than with the nivolumab plus ipilumumab combination (pneumonitis [6%]). 8 In the phase 3 CheckMate 067 trial, 8 55% of patients receiving the combination of nivolumab plus ipilimumab had grade 3-4 treatment-related adverse events after a median follow-up of 9 months, with prevalence increasing to 59% after a minimum follow-up of 28 months, 18 whereas these adverse events occurred in only 45% of patients receiving pembrolizumab plus ipilimumab in this trial after a median follow-up of 17 months. Most immune-mediated adverse events in this trial occurred within the first 6 months of treatment. Furthermore, 72% of patients in this trial were able to receive all four doses of combination therapy, and 67% of all and 79% of grade 3-4 treatment-related adverse events had resolved by data cutoff.
The 61% of patients with an objective response to pembrolizumab plus ipilimumab in this study is higher than the proportion reported for anti-PD-1 monotherapy, which ranges from 20% to 45% depending on the number of previous treatments, and the 15% of patients with a complete response in this study is higher than most other estimates, which range from 2% to 15%, again depending on the number of previous treatments. 4, 6, 7, 9, 18 We observed a high proportion of patients with an objective response across all major subgroups, including patients with poor prognostic characteristics or those with a BRAF V600 mutation or PD-L1-negative tumours. These findings are similar to those observed with nivolumab plus ipilimumab, which seems to have a greater benefit compared with nivolumab monotherapy in patients with PD-L1-negative tumours than in those with PD-L1-positive tumours. 18, 24 However, between-study comparisons of subgroups should be interpreted with caution given the absence of power for these analyses in both studies.
The proportions of patients with an objective (61%) and complete (15%) response observed with standard-dose pembrolizumab plus reduced-dose ipilimumab are consistent with those observed in phase 2 17 (objective response 59% and complete response 22%) and 3 18 (59% and 17%) trials of reduced-dose nivolumab plus standard-dose ipilimumab. Cross-trial comparisons should be interpreted with caution given the potential for imbalances in known prognostic and predictive variables, such as serum lactate dehydrogenase concentrations, burden of disease, and baseline PD-L1 expression status. 25, 26 Comparison of PD-L1 expression is complicated by use of different assays and definitions of positivity in the KEYNOTE 4, 6, 27 and CheckMate 8, 17, 24 trials, resulting in a consistently different proportion of PD-L1 positivity between them. In this phase 1 trial, 25% of patients had an elevated serum lactate dehydrogenase concentration at baseline, a factor strongly associated with poorer response and survival in patients receiving immuno therapy than in those with normal concentrations, whereas the frequency reported in phase 3 trials [6] [7] [8] 28 of patients with metastatic melanoma ranges from 35% to 40%. Additionally, the relative contribution of PD-1 and CTLA-4 inhibition to long-term efficacy and survival afforded by the combination is unclear. Although CheckMate 067 8 was not powered for the comparison of nivolumab plus ipilimumab with nivolumab alone, the overall survival analysis 18 showed similar estimated overall survival proportions at 1 year (73% for nivolumab plus ipilimumab vs 74% for nivolumab alone) and 2 years (64% vs 59%). Furthermore, although results from a phase 3 trial 29 of ipilimumab 10 mg/kg versus 3 mg/kg showed a clear dose-response relationship in patients with metastatic melanoma, they do not address the question of whether or not a dose-response relationship exists for anti-CTLA-4 therapy when combined with anti-PD-1 therapy.
The combination of standard-dose pembrolizumab with reduced-dose ipilimumab was highly active, with a tolerable toxicity profile. Further analyses based on longer follow-up than we reported here will be done to define the survival benefit and duration of response of this combination. However, whether or not the reduced dose of ipilimumab used in this study is sufficient to maintain response in the long term and provides anti-tumour activity comparable with that of standard-dose ipilimumab when combined with anti-PD-1 therapy and better than that of anti-PD-1 monotherapy can only be established in an appropriately powered randomised trial. A phase 3 randomised trial of standard-dose nivolumab plus reduced-dose ipilimumab versus reduced-dose nivolumab plus standard-dose ipilimumab for advanced melanoma is underway (NCT02714218) and should help to answer questions regarding the relative efficacy and safety of the two combination strategies. In lieu of the originally planned phase 2 part of the KEYNOTE-029 trial, a randomised cohort exploring pembrolizumab 200 mg every 3 weeks plus four doses of ipilimumab at either 50 mg every 6 weeks or 100 mg every 12 weeks has been opened for enrolment. In an effort to improve the efficacy of anti-PD-1 monotherapy with a minimal increase in toxicity, other pembrolizumab-based combinations are being examined in randomised controlled trials, including combinations with the oncolytic viral therapy talimogene laherparepvec (NCT02263508) and the indoleamine 2,3-dioxygenase inhibitor epacadostat (NCT02752074). 
